Monitor for data readout from Part A and initiation of Part B. The stock is highly speculative given the $3M market cap and lack of disclosed efficacy data. Traders should watch for catalyst-driven volatility.
Price Chart
Executive Summary
Clearmind Medicine announced the successful completion of treatment for all 24 participants in Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder. The company is now reviewing data and intends to initiate the next stage of the clinical program if results remain favorable. This is a positive operational milestone for a clinical-stage biotech with a $3M market cap, but no efficacy data or financial figures were disclosed.
Key Facts
- All 24 participants across Cohorts 1-4 completed Part A of the Phase I/II trial for CMND-100 (Alcohol Use Disorder).
- The trial is conducted under FDA oversight at sites including Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- No safety, efficacy, or financial data were disclosed; the company is currently assessing the dataset.
- Clearmind has a market cap of approximately $3M and is a clinical-stage biotech with 19 patent families and 32 granted patents.
- Recent insider activity includes $330K in buys and $119K in sells over the past 30 days.
Financial Impact
No financial figures disclosed; market cap ~$3M. Positive trial progress may support valuation but no quantifiable impact.
Risk Factors
- No efficacy or safety data disclosed; results may not support advancement.
- Clinical-stage biotech with no approved products; high risk of failure.
- Forward-looking statements are subject to significant uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315267 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers